Clinical trial strategy: Fine-tuning the risk-reward profile

Swiss Biotech Insights - 1/2 Day event

Trial design remains a challenge, and development the longest and most expensive component of the Biotech value creation.

The Swiss Biotech Association and Parexel invite you to Lausanne on Sept 19th for this exciting event to address major clinical trial strategy challenges. Hear from world-renowned speakers and discuss the growing complexity of trials while exploring exciting new opportunities including real world data science, adaptive clinical trial design, biomarkers and more.

The Swiss Biotech Association is launching the Swiss biotech Insight event series, designed to cover a portfolio of topics mirroring the biopharma product life cycle, namely from ideation and research to commercialization and patient benefit. The three main areas covered are discovery, development and commercialization.

Informazioni

Data
Pubblico target	Biotech, Pharmaceutical and Medtech Companies, Multinationals, SMEs and Start Ups
Organizzatore	Swiss Biotech Association
Lingua dell’evento	English
Costi di partecipazione	CHF 50 for Swiss Biotech Association Members and CHF 100 for everyone else
Relatori	Dr. Olaf Ritzeler, Director, Rare Diseases External Innovation, Sanofi From No to Yes: What are licensing partners looking for? Matthias Grossmann, VP, Parexel Early Phase Scientific Affairs The fast lane to proof of concept Dr. Andrew Galazka, MD, Senior VP, Head of Global Medical Excellence at Merck Clinical development strategies: lessons learnt and implications for the future Dr. Jens Wuerthner, Head of Clinical Development, ADC Therapeutics Current challenges in oncology development Dr. Justin Devine, Chief Medical Officer, Synexa Group Life Sciences Using biomarkers to improve the quality of decision making in drug development Claudia Graeve, VP, Health Advances Real world data science and the future of clinical trial design Pantelis Vlachos, Principal Strategic Consultant, Cytel Inc Adaptive designs: Statistical, operational and regulatory issues Philippe Menu, McKinsey & Company New frontiers in pharma R&D investment: Sharing risks and rewards over product development cycle Christian Fehr, Relationship Manager Primary Markets, and Valeria Ceccarelli, Head Primary Markets, SIX IPO on SIX: The leadership team also goes public Dr. Victor Cheng, Vice President, Technical, Parexel China The China opportunity: Considerations for clinical strategy